jeudi 19 novembre 2015

Onco Actu du 19 novembre 2015

3.1 Tabac

Joe Nocera’s contentious e-cigarette crusade [HealthNewsReview]

3.3 Prévention - Vaccins

Give HPV vaccine to men who have sex with men, government told [The Guardian]

4. Dépistage, diagnostic et pronostic

Study Advances Potential Test to Sort Out Precancerous Pancreatic Cysts From More Harmless Ones [Johns Hopkins]

Can pigeons home in on cancer? [Cancer Research UK]

Pigeons tend to land on the right spot when looking for breast cancer [Reuters]

4.12 Biopsies liquides

Blood test detects ovarian cancer in nine out of 10 patients [The Telegraph]

4.9 Dép., diag. & prono. - Sein

Prospective Validation of a 21-Gene Expression Assay (OncotypeDX) in Breast Cancer [Now@NEJM]

5.2 Pharma

Pfizer Reports Positive Topline Results from Phase 3 Trial Comparing XALKORI® (crizotinib) to Chemotherapy in Previously Untreated East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) [Pfizer]

New Long-Term Data on Opdivo and the Opdivo + Yervoy Regimen Shows Survival Benefit Across Lines of Therapy in Advanced Melanoma [BMS]

Servier and Pfizer get rights to Cellectis cancer cell therapy [Reuters]

5.2.1 Pharma - Partenariats

Lilly and Merck Expand Immuno-oncology Collaboration with Phase III Nonsquamous Non-Small Cell Lung Cancer Trial [Merck]

5.2.2 Pharma - Fusions & Acquisitions

Pfizer close to record-breaking Allergan deal at up to $380 per share: Bloomberg [FiercePharma]

5.3 Traitements - FDA, EMA,...

Merck KGaA, Pfizer bag 'breakthrough' status for PD-L1 immunotherapy [FierceBiotech]

Merck KGaA, Darmstadt, Germany, and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma [Pfizer]

Approvals (and Otherwise) in Oncology [In the Pipeline]

5.4 Traitements - Economie

NICE says 'no' to personalised bowel cancer drugs [PharmaTimes]

NICE decision restricts Bayer’s Xofigo to select prostate cancer patients [Pharmafile]

6. Lutte contre les cancers

The Cost of Cancer Disparities [CANCER RESEARCH Catalyst]

6.1 Observation

Childhood cancers more likely to come from major cancer genes than scientists thought [Science]

Many children with cancer were born at risk: U.S. study [Reuters]

6.10 Politiques

Decision time for new EU rules on how researchers use personal data [Cancer Research UK]

6.6 Publications

MD Anderson researcher Aggarwal up to six corrections [Retraction Watch]

6.9 Controverses

J&J Says There Were No Reportable Morcellation Events; Whistleblower Disagrees—and Produces Letters [The Cancer Letter]

Congressional Panel Chair Questions Whether J&J, Brigham Reported Morcellation Adverse Events to FDA [The Cancer Letter]